Authours: Olugbenga M. AJULO1* and Faith A. ESHIET2

 Department of Clinical Pharmacy & Biopharmacy, Faculty of Pharmacy,University of Uyo. Uyo. Akwa-Ibom State. Nigeria1

Faculty of Pharmacy,University of Uyo, Uyo. Akwa-IBom State. Nigeria2

*Correspondence:, ,+2347030262468; +2348113390091



Background: Antimalaria combination therapy is the simultaneous use of two or more blood schizontocidal drugs with independent modes of action and different biochemical targets on malaria parasites. Presently, 90% of global episodes of clinical malaria and malaria mortality occur in sub-Saharan Africa. Malaria control efforts in the region were greatly affected by the emergence and spread of chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistant plasmodium species. Artemisinin-based combination therapies (ACTs) was shown to improve treatment efficacy and curtailed drug resistance. The study aimed at comparing the post-treatment protection period as benefit with cost of procuring antimalarial drugs by consumers.

Method: The University Health Center, Uyo was selected for the study by convenience sampling. Ethical approval was obtained from the Center. Case notes of 118 patients on antimalaria prescriptions attending the Center for treatment of uncomplicated malaria from January 1st 2004 to December 31st 2013 were surveyed. Information such as age, sex, names and time of prescribed antimalarial drugs were collated. Protection period was measured by time interval between two antimalarial prescriptions. Statistical analysis was computed by using SPSS version 21 software packages. Statistical significance level was set at p=0.05.

Result: A total of one thousand three hundred and sixty-five (1365) antimalarial prescriptions were collated among patients of different age groups ranging from 0 to 79 years. Four hundred and eighty-four (484) and eight hundred eighty-one (881) antimalarial prescriptions were received by male and female patients respectively. Antimalarial single therapy (558, 40.87%) was prescribed mostly in 2004 while ACT (443, 32.45%) and other combination therapies (323, 23.66%) were used predominantly after 2004. SP (208, 37.27%) and Artemether + Lumefantrine (AL) (309, 69.75%) were the most frequently prescribed antimalarial single therapy and approved ACT respectively. The protection period of antimalarial single therapy was highest for Artesunate (233.75±31.92days). The protection period of antimalarial combination therapy approved as ACT was highest for Artesunate + Amodiaquine (AA) (192.51±24.28days).

Conclusion: This study showed that none of the recommended artemisinin-based combination therapies produced protection period as when artesunate was used alone. AA was shown to have the best cost-benefit among all the four recommended ACTs.

Key words: Artemisinin-based Combination Therapies, Sulphadoxine-Pyrimethamine, Chloroquine, Cost-benefit, Protection Period



  1. World Health Organization (2005). World Malaria report.
  2. WHO 2015. WHO Global Malaria Program: World Malaria report
  3. United Nations Children’s Emergency Fund (2010). Progress and impact series. World Malaria Day 2010: Africa Update.
  4. Roll Back Malaria (2010). World Malaria Day 2010: Africa Update. Progress and Impact Series. Number 2.
  5. Bello RA. (2004). Costing the socio-economic effects of malaria in Nigeria. Indian development review 2 (2): 131-140.
  6. Chanda P, Masiye F, Chitah BM, Sipilanyambe N, Hawela M, Banda P and Okorosobo T (2007). A cost effectiveness analysis of artemether lumenfantrine for treatment of uncomplicated malaria in Zambia. Malaria journal 6: 21.
  7. World Health Organisation (2001). Antimalaria drug combination therapy. Geneva
  8. Federal Ministry of Health (2005). National antimalaria treatment policy.
  9. Koram KA, Abuaku B, Duah N and Quashie N (2005). Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta tropica 95(3): 194-203.
  10. Suleiman IA, Onyemeze BB, Ganiyu KA (2015). Prevention, management and cost implications of malaria in Niger Delta, Southern Nigeria. The Nigerian Journal of Pharmacy 49(2): 37-45.
  11. Soe S, Micheal T, Christian R,Khin-Saw-Aye and Pierre D (2004). Association between protection against clinical malaria and antibodies to merozoites surface antigens in an area of hyperendemicity in Myanmar: Complementarity between responses to merozoites surface protein 3 and the 220-kilodalton glutamate rich protein. Infection and immunity 72 (1): 247-252.
  12. WHO 2015. Guidelines for the treatment of malaria. Third Edition.
  13. Babwah F, Baksh SBlake LCupid-Thuesday JHosein ISookhai APoon-King CHutchinson G The role of gender in compliance and attendance at an outpatient clinic for type 2 diabetes mellitus in Trinidad. Rev Panam Salud Publica.19(2):79-84.
  14. Akaji EA,Chukwuneke FNOkeke UF Attendance pattern amongst patients at the Dental Clinic of the University of Nigeria Teaching Hospital, Enugu, Nigeria. Niger J Med. 21(1):74-7.
  15. Nosten F and White NJ (2007). Artemisinin-based combination treatment of Falciparum Malaria. Am J Trop Med Hyg 77 (Suppl6): 181-192.
  16. World Health Organization: Guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108
  17. World Health Organization 2005. The Roll Back Malaria strategy for improving access to treatment of malaria through home management of malaria. In WHO/HTM/MAL/2005/1101 Geneva, World Health Organization.
  18. World Health Organization: Facts on Artemisinin-based combination therapies, Geneva January 2006 update.http:/ / RBMInfosheet_9.
  19. Suputtamongkol Y, Newton PN, Angus B, Teja-Isavadharm P, Keeratithakul D, Rasameesoraj M, Pukrittayakamee S and White NJ (2001). A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Br J Clin Pharmacol, 52, 655-661.
  20. Bretscher MT, Griffin JT, Hugo P, Baker M, Ghani A and Okell L, (2014). A comparison of the duration of treatment protection of artemether + lumefantrine, dihydroartemisinin-piperaquine and artesunate amodiaquine for the treatment of uncomplicated malaria. Malaria journal 13 (1): 19.
  21. Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P (2014). Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev 10:CD000169.
  22. Kayentao K, Garner P, van Ejik AM, Naidoo I, Roper C, Mulokozi A, et al. (2013). Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulphadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA 309 (6): 594-604.
  23. Garner P, Gulmezoglu AM, drugs for preventing malaria-related illness in pregnant women and death in the new born. Cochrane Database Syst Rev 2003(1): CD000169.
  24. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J et al., (2009). Efficacy and safety of intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-control trials. Lancet 374 (9700): 1533-1542.
  25. Winthrop (2010). WHO prequalification Program. WHO public assessment report. Artesunate–AmodiaquineWinthrop.VI:1-11.
  26. World Health Organisation (2015). Emergency response to artemisinin resistance in the Greater Mekong subregion: regional framework for action 2013-2015.
  27. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, Talisuna A, Kironde F, Nsobya SL, Kilian A, Slater M, Reingold A, Rosenthal PJ, Wabwire-Mangen F and Dorsey G (2005). Artemisinin versus Nonartemisinin Combination Therapy for Uncomplicated Malaria: Randomized Clinical Trials from Four Sites in Uganda. PlosMedicine 2(7):1-9 e190. DOI: 10.1371/journal.pmed.0020190.
Close Menu